Trial reportThe Journal of infectious diseases2019
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.
Trial report in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of MVA-EBO Z Alone and a Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy UK Volunteers
A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Effects of schistosomes on host anti-viral immune response and the acquisition, virulence, and prevention of viral infections: A systematic review.PLoS pathogens · 2021Pooled it
- Cohort profile: the Entebbe Mother and Baby Study (EMaBS).BMJ open · 2026Trial
- Schistosome and malaria exposure and urban-rural differences in vaccine responses in Uganda: a causal mediation analysis using data from three linked randomised controlled trials.The Lancet. Global health · 2024Trial
- Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells.The Journal of experimental medicine · 2020Trial
- Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.Journal for immunotherapy of cancer · 2020Trial
- The human immunome in the post-schistosomiasis mass drug administration era.PLoS neglected tropical diseases · 2026Review
- The endemic dilemma: why whole sporozoite malaria vaccine efficacy falls in the field.Trends in parasitology · 2026Review
- Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025Review
- Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters.NPJ vaccines · 2025Article
- Global disparities in the introduction, scale-up, and effectiveness evaluation of COVID-19 vaccines.Nature communications · 2025Article
- Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity.NPJ vaccines · 2025Article
- Helminth driven gut inflammation and microbial translocation associate with altered vaccine responses in rural Uganda.NPJ vaccines · 2025Article
- Article
- The Application of DNA Viruses to Biotechnology.Viruses · 2025Review
- Molecular Mechanism of VSV-Vectored ASFV Vaccine Activating Immune Response in DCs.Veterinary sciences · 2025Article
- Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection.EBioMedicine · 2024Article
- Intranasal Prime-Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection.Vaccines · 2024Article
- Immunological factors linked to geographical variation in vaccine responses.Nature reviews. Immunology · 2024Review
- Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.NPJ vaccines · 2024Article
- Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.Lancet (London, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundThe 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an effective Ebola vaccine.
methodsWe undertook 2 phase 1 studies assessing safety and immunogenicity of the viral vector modified vaccinia Ankara virus vectored Ebola Zaire vaccine (MVA-EBO-Z), manufactured rapidly on a new duck cell line either alone or in a heterologous prime-boost regimen with recombinant chimpanzee adenovirus type 3 vectored Ebola Zaire vaccine (ChAd3-EBO-Z) followed by MVA-EBO-Z. Adult volunteers in the United Kingdom (n = 38) and Senegal (n = 40) were vaccinated and an accelerated 1-week prime-boost regimen was assessed in Senegal. Safety was assessed by active and passive collection of local and systemic adverse events.
resultsThe standard and accelerated heterologous prime-boost regimens were well-tolerated and elicited potent cellular and humoral immunogenicity in the United Kingdom and Senegal, but vaccine-induced antibody responses were significantly lower in Senegal. Cellular immune responses measured by flow cytometry were significantly greater in African vaccinees receiving ChAd3 and MVA vaccines in the same rather than the contralateral limb.
conclusionsMVA biomanufactured on an immortalized duck cell line shows potential for very large-scale manufacturing with lower cost of goods. This first trial of MVA-EBO-Z in humans encourages further testing in phase 2 studies, with the 1-week prime-boost interval regimen appearing to be particularly suitable for outbreak control. CLINICAL TRIALS REGISTRATION: NCT02451891; NCT02485912.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.